Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Immucell Corp changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 27 | 25 | −2 |
| Shares | 1.21M | 1.31M | +103.5K (+8.6%) |
| Value | $5.79M | $9.00M | +$3.21M (+55.5%) |
New holders (1)
Institutions that held Immucell Corp at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Raymond James Financial Inc | 1,970 | $13.7K | 0.00% |
Sold out (3)
Institutions that held Immucell Corp at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Susquehanna International Group, LLP | 13,501 | $64.7K |
| Tower Research Capital LLC (TRC) | 1,017 | $4.87K |
| JPMorgan Chase & Co | 10 | $48 |